Formulation and evaluation of flurbiprofen microemulsion.
The purpose of the present study was to investigate the microemulsion formulations for topical delivery of Flurbiprofen (FP) in order to by pass its gastrointestinal adverse effects. The pseudoternary phase diagrams were developed and various microemulsion formulations were prepared using Isopropyl Myristate (IPM), Ethyl Oleate (EO) as oils, Aerosol OT as surfactant and Sorbitan Monooleate as cosurfactant. The transdermal permeability of flurbiprofen from microemulsions containing IPM and EO as two different oil phases was analyzed using Keshary-Chien diffusion cell through excised rat skin. Flurbiprofen showed higher in vitro permeation from IPM as compared to that of from EO microemulsion. Thus microemulsion containing IPM as oil phase were selected for optimization. The optimization was carried out using 2(3) factorial design. The optimized formula was then subjected to in vivo anti-inflammatory study and the performance of flurbiprofen from optimized formulation was compared with that of gel cream. Flurbiprofen from optimized microemulsion formulation was found to be more effective as compared to gel cream in inhibiting the carrageenan induced rat paw edema at all time intervals. Histopathological investigation of rat skin revealed the safety of microemulsion formulation for topical use. Thus the present study indicates that, microemulsion can be a promising vehicle for the topical delivery of flurbiprofen.
Ambade
K W
KW
Department of Pharmaceutics, Bharati Vidyapeeth's College of Pharmacy, CBD Belapur, Sector-8, Navi-Mumbai, India.
Jadhav
S L
SL
Gambhire
M N
MN
Kurmi
S D
SD
Kadam
V J
VJ
Jadhav
K R
KR
D000287:Administration, Topical; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D004143:Dioctyl Sulfosuccinic Acid; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D004655:Emulsions; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D005782:Gels; D006601:Hexoses; D066298:In Vitro Techniques; D008297:Male; D009226:Myristates; D009829:Oleic Acids; D010316:Particle Size; D010539:Permeability; D051381:Rats; D017208:Rats, Wistar; D012212:Rheology; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012869:Skin Absorption; D012995:Solubility; D013501:Surface-Active Agents; D014783:Viscosity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004655:Emulsions; D005782:Gels; D006601:Hexoses; D009226:Myristates; D009829:Oleic Acids; D013501:Surface-Active Agents; C018665:sorbitan monooleate; C008205:isopropyl myristate; D004143:Dioctyl Sulfosuccinic Acid; D005480:Flurbiprofen; C033180:ethyl oleate